IARC launches the Lung Cancer Cohort Consortium (LC3) website

A new website from the International Agency for Research on Cancer (IARC) presents the Lung Cancer Cohort Consortium (LC3).

The centralized LC3 database includes risk factor and clinical information from more than 3 million longitudinally followed research participants, including 70 000 incident lung cancer cases. It provides an unprecedented resource to study lung cancer risk in North America, Europe, Asia, the Middle East, and Oceania.

The LC3 has a well-established legal and technical infrastructure that allows external investigators to request permission to remotely analyse the data in a secure computing environment. Details about the available variables in the database were published in an article in Annals of Epidemiology, and further information on how to request access to the LC3 data is available on the LC3 website.

The LC3 is led by Dr Mattias Johansson and Dr Hilary Robbins, scientists in the Genomic Epidemiology Branch at IARC, and aims to facilitate collaborative research on lung cancer etiology, risk assessment, and early detection. Since its inception in 2010, the LC3 has been continuously supported through several grants from the United States National Cancer Institute. The most recent round of funding focused on systematically assessing and validating biomarkers for lung cancer early detection, as well as developing and validating biomarker-based lung cancer risk models.

Visit the Lung Cancer Cohort Consortium (LC3) website 

Read the information about the available variables in the Annals of Epidemiology article “Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program”

Read the LC3 Access Policy 

Read the LC3 Design Paper

View the LC3 Data Access Proposal form